16.7% YTD return hails Fidelity European Trust’s strong credentials

Fidelity

Fidelity European Trust PLC (LON:FEV) monthly factsheet for June 2025.

Portfolio Manager Commentary

Continental European equities ended the month slightly lower (in euro terms) following a strong year-to-date performance. Investor sentiment was impacted by geopolitical uncertainty, particularly towards the end of the month, amid the Israel-Iran conflict, while trade tensions continued to weigh on risk appetite ahead of the 9 July deadline for US trade negotiations. 

The Trust underperformed the index during the month, mainly due to weak stock selection in industrials, technology, and healthcare, though overall sector positioning had a small positive impact. Flavours & fragrances business Symrise was the largest detractor over the period, with shares falling on concerns of a Q2 slowdown driven by macroeconomic headwinds. Shares in Nestlé were weak following the announcement of Chairman Paul Bulke’s planned departure in April 2026 amidst ongoing pressures from subdued consumer demand and rising input costs. In contrast, Legrand shares continued to deliver strong performance underpinned by its strong Q1 2025 results announced in May. The holding in EQT also performed well supported by multiple broker upgrades. 

Our focus is on finding attractively valued companies with good prospects for cash generation and dividend growth over the longer term. On a rolling 12-month basis, the Trust recorded NAV and share price returns of 2.3% and 5.5% respectively, compared to FTSE World Europe ex UK Total Return Index that returned 9.9%.  

Fidelity European Trust PLC (LON:FEV) aims to be the cornerstone long-term investment of choice for those seeking European exposure across market cycles.

Share on:
Find more news, interviews, share price & company profile here for:

Are European equities set for a revival?

Marcel Stötzel, Co-Portfolio Manager of Fidelity European Trust, remains positive on Europe’s investment outlook, citing structural reforms, rising defence spending and potential economic integration as key drivers.

Fidelity European Trust continued rise as shares advanced in ASML and AIB

Fidelity European Trust has published its September 2025 factsheet, noting European equities finished the quarter higher despite mixed sector performance.

Investing in Europe: Why investors should remain positive

Co-Portfolio Manager of the Fidelity European Trust PLC (LON:FEV), outlines why he believes quality businesses backed by strong balance sheets and dividend growth potential remain well placed to deliver strong relative returns over the long-term.

Fidelity European Trust rises in August, reporting 16.4% returns in 2025

Fidelity European Trust highlighted strong contributions in August 2025 from KBC Groupe, which upgraded full year guidance, and Novo Nordisk, which advanced on positive trial results and regulatory approval for Wegovy.

Fidelity European Trust Factsheet – July volatility, Legrand and Bankinter gains

Continental European equities were volatile in July, with the Trust underperforming the index due to weak stock selection in financials and healthcare. Novo Nordisk and ASML detracted, while Legrand and Bankinter contributed positively. Over 12 months, the Trust’s NAV rose 1.8% and the share price 1.7%, compared with an 11.3% gain for the index.

European Investment Opportunities – Fidelity’s Quality Focus (LON:FEV)

FEV portfolio manager Marcel Stotzel highlights how quality companies with strong defensive characteristics can help investors navigate uncertainty and achieve long-term growth.

Search

Search